Accuray (ARAY) Q3 2026 earnings review
Guidance Pulled as Geopolitical Headwinds Mount
Accuray's turnaround story hit a major roadblock in Q3. Revenue fell 7% YoY to $104.8 million, and net loss widened drastically from $1.3 million a year ago to $11.8 million. While management touted $10 million in cost savings from their transformation plan, the broader picture is concerning: gross margins compressed to 24.1%, order backlog plunged 21%, and the company entirely withdrew its FY26 financial guidance. After spending the first half of the year blaming China tariffs, management is now citing geopolitical unpredictability in the Middle East as the primary catalyst for delayed shipments and service disruption.
🐂 Bull Case
The company has realized ~$10 million in margin and cost improvements through Q3, positioning it to exceed its original $12 million target for FY26. Operating expenses (excluding restructuring) fell 9% YoY.
While product revenue collapsed 13%, service revenue held relatively steady at $55.1 million (-1% YoY), continuing to act as a buffer against capital equipment volatility.
🐻 Bear Case
Pulling full-year guidance entirely due to Middle East uncertainty signals severe pipeline visibility issues. It leaves investors completely in the dark regarding near-term cash flow and profitability.
Gross orders plummeted 32% YoY to $48.5 million. A shrinking backlog ($356.2 million, down 21% YoY) indicates future revenue contraction is highly likely.
⚖️ Verdict: 🔴
Bearish. A transformation plan cannot offset a deteriorating top-line and collapsing gross margins. Withdrawing guidance creates an unacceptable level of uncertainty for investors in a capital-intensive business.
Key Themes
Middle East Disruption Forces Guidance Withdrawal
Macro Picture: In prior quarters, Accuray blamed China tariffs for revenue misses. Now, the narrative has shifted to the Middle East. Management withdrew FY26 revenue and Adjusted EBITDA guidance entirely, citing geopolitical uncertainty materially delaying product shipments and service installations in several markets. This represents a severe break in operational visibility.
Margin Squeeze Contradicts Transformation Progress
While management praised the ~$10 million in cost savings from their transformation plan, the raw data contradicts this rosy picture at the gross profit level. Total gross margin decelerated to 24.1% from 27.9% a year ago. The company specifically cited $3.2 million in higher net parts consumption and elevated logistics and duties costs, indicating structural inefficiencies remain unresolved.
Aggressive Cost Restructuring
The primary defense mechanism protecting the bottom line is aggressive cost-cutting. The company incurred $6.5 million in restructuring charges this quarter, but excluding those, operating expenses fell 9% YoY. Management expects to surpass their $12 million FY26 target for margin and cost improvements, which is critical given the top-line contraction.
Commercial Leadership Overhaul
In a bid to fix the broken order pipeline, Paul Miele was appointed Chief Commercial Officer. His mandate is to scale the capital medical device business and accelerate profitable growth. Given the 32% plunge in gross orders this quarter, stabilizing the commercial engine will be his immediate and most urgent challenge.
Real-Time Adaptation Technology Highlights
Product Innovation: Accuray is leaning into its core differentiator—real-time adaptation to patient and tumor motion. The company plans to showcase practical, customer-driven product enhancements at the upcoming European Society for Radiotherapy and Oncology (ESTRO) Congress. Enhancing workflow efficiency and clinical excellence is vital to jumpstarting the stalled replacement cycle in developed markets.
Service Revenue Flattens Out
Service revenue—historically Accuray's reliable growth engine and margin protector—reversed its growth trend, falling 1% YoY to $55.1 million. While product revenue declines are expected due to capital cycle volatility, stagnation in the recurring service base is a red flag that requires immediate monitoring.
Other KPIs
Decelerating. Down 13% YoY compared to $57.3 million in Q3 FY25. This marks the third consecutive quarter of severe double-digit product revenue contraction, reflecting stalled capital equipment purchases and delayed installations globally.
Reversing. Down from $47.9 million at the end of Q2 and a significant drop from $62.1 million at the end of FY25. Cash burn is accelerating due to restructuring payouts and continued operating losses, reducing the company's financial cushion.
Decelerating. Down from $6.0 million in the prior year period. While it represents an improvement from the negative EBITDA seen in Q1 and Q2 of this year, the YoY deterioration underscores the heavy toll of margin compression and volume loss.
Guidance
Management formally withdrew its previous revenue guidance of $440-$450 million. The company cited the inability to predict the timing of installations in several key Middle Eastern markets due to the current geopolitical environment.
Previously set at $22-$25 million, this target was also pulled. Given the severe gross margin compression to 24.1% in Q3, achieving the prior EBITDA target was likely already in jeopardy even without the Middle East disruptions.
Key Questions
Middle East Revenue Exposure
With guidance withdrawn entirely due to Middle East geopolitical issues, what is the exact percentage of the $356.2 million backlog tied to this region, and are there risks of outright cancellations rather than just delays?
Service Revenue Contraction
Service revenue declined 1% YoY after growing in previous quarters. Is this decline solely tied to delayed new installations, or are you seeing elevated churn/pricing pressure in the existing contract base?
Timeline for Gross Margin Recovery
Gross margins compressed to 24.1% driven by logistics and parts consumption. Are these inflationary pressures structural, and when do you expect the $10M+ in transformation savings to reflect visibly in the gross margin line?
Cash Burn Runway
Total cash has fallen from $62 million at year-end to $44.4 million. Given the ongoing restructuring charges and delayed revenue recognition, what are the minimum liquidity covenants on your debt, and is further financing necessary?